Extended Data Fig. 8: Outcome according to baseline IFNγ and PD-L1 for the conformation-cohort OpACIN-neo. | Nature Medicine

Extended Data Fig. 8: Outcome according to baseline IFNγ and PD-L1 for the conformation-cohort OpACIN-neo.

From: Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

Extended Data Fig. 8

a, Bar plot showing percentage of patients achieving MPR (including 95% confidence interval) according to baseline IFNγ and PD-L1: low IFNγ and low PD-L1 (n = 19); low IFNγ and high PD-L1 (n = 11); high IFNγ and low PD-L1 (n = 8); high IFNγ and high PD-L1 (n = 7). b, Kaplan−Meier curves, including log-rank P value for EFS, showing EFS according to IFNγ and PD-L1 subgroups as described at a. c,d, Kaplan−Meier curves, including log-rank P value for EFS, in patients with a low IFNγ and low PD-L1 (n = 19) versus all other biomarker combinations (n = 26) (c), and in patients with a high IFNγ and high PD-L1 (n = 7) versus all other biomarker combinations (n = 38) (d). e-f, ROC curves for low IFNγ and low PD-L1 versus all other biomarker combinations (AUC = 0.565) (e), and high IFNγ and high PD-L1 versus all other biomarker combinations (AUC = 0.6) (f). The ROC curve analyses used a binary outcome (event within five years), since follow-up among all event-free patients was ≥58 months.

Back to article page